Arrow Icon Back to News

Atalanta Therapeutics Strengthens Leadership Team with Key Appointments in R&D and Corporate Development

BOSTON, October 7, 2021 – Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, today announced the expansion of its leadership team with three new appointments: Morgan Molloy as chief corporate development officer; Stefan McDonough as vice president, head of neuroscience; and Garth Kinberger as vice president of chemistry.

“We are thrilled to welcome these accomplished professionals to Atalanta as we grow our pipeline, expand our team, and chart the company’s future direction,” said Alicia Secor, president and chief executive officer. “Stefan and Garth’s leadership will be instrumental in progressing our newly defined, wholly-owned pipeline programs utilizing branched siRNA to address neurodegenerative and, more broadly, CNS diseases. Morgan’s operating experience will help scale our organizational structure and position us for continued successes going forward.”

Morgan Molloy joins Atalanta as chief corporate development officer with more than 25 years of operational and commercial leadership experience in the biopharmaceutical industry, with specific expertise in business strategy and organizational growth. He most recently served as chief corporate development officer at Akouos. Prior to Akouos, Mr. Molloy was chief commercial officer at Enzyvant. Earlier in his career he held leadership roles at Spark Therapeutics, Genzyme and Biogen. He holds a B.S. in business management with concentrations in finance and marketing from the University of Massachusetts, Lowell.

Stefan McDonough, Ph.D., joins Atalanta as vice president, head of neuroscience with nearly 20 years of expertise in genetics and in neuroscience drug discovery and development. He most recently served as executive director, genetics at Pfizer, prior to which he was the company’s head of neurogenetics. Earlier in his career, Dr. McDonough spent 12 years at Amgen in scientific roles of increasing responsibility in the neuroscience department and as head of Amgen’s genome analysis unit. He holds a Ph.D. in biology from Caltech, and completed postdoctoral studies at Harvard Medical School and University of Maryland Medical School. He is author on over 40 peer-reviewed publications and serves on the advisory board of the Carney Institute for Brain Science at Brown University.

Garth Kinberger, Ph.D., joins Atalanta as vice president of chemistry, bringing nearly 20 years of experience in RNA drug development. Prior to Atalanta, he held a number of chemistry roles of increasing responsibility at Regulus Therapeutics, culminating in the role of executive director of chemistry, CMC and pharmaceutical development. Prior to Regulus, Dr. Kinberger was at Ionis for 13 years. He is named as a co-author or inventor on more than 30 peer-reviewed articles and patents. He holds a Ph.D. in chemistry from the University of California San Diego.

About Atalanta Therapeutics

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform. Atalanta was founded in 2018 by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital and strategic collaborations with Biogen and Genentech. Atalanta is headquartered in Boston, Mass. For more information, visit and follow us on Twitter and LinkedIn.

Your browser is out of date!

Update your browser to view this website correctly. Update my browser now